The PCOS-IR+GPR120 agonist, PCOS-IR+LrB (40 mg/kg), and PCOS-IR+LrB (20 mg/kg) groups presented significant decreases in LH and T and LH/FSH ratio (Figure 7A,C) and significant increases in FSH and E2 levels (Figure 7D,E) in comparison with PCOS-IR. The gene discussed is BRD2; the disease is polycystic ovary syndrome.